Wells Fargo’s Belite Bio BLTE Stock Holding History

Wells Fargo’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.8K	Buy	124 +24	+24%	+$4.04K	﹤0.01%	5775
2025 Q4	$16K	Buy	+100	New	+$11.8K	﹤0.01%	5847

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's BLTE Position: Q1 2026 in Review

Wells Fargo increased its Belite Bio (BLTE) stake by 24% in Q1 2026, buying an estimated $4.04K and bringing the position to 124 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5775.

Wells Fargo first reported a position in BLTE in Q4 2025 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Wells Fargo held 124 shares of Belite Bio worth $19.8K as of Q1 2026.
Wells Fargo bought 24 Belite Bio shares in Q1 2026, an estimated $4.04K.
Belite Bio made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5775 holding.
Wells Fargo first reported a position in Belite Bio in Q4 2025 and has held it in 2 quarters since.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.